Oruka Therapeutics’ (ORKA) “Outperform” Rating Reaffirmed at Wedbush

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reissued by Wedbush in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $165.00 price objective on the stock. Wedbush‘s target price would indicate a potential upside of 72.37% from the stock’s current price.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. HC Wainwright restated a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $133.00.

Oruka Therapeutics Stock Performance

ORKA traded up $5.40 during trading on Tuesday, hitting $95.73. The stock had a trading volume of 830,487 shares, compared to its average volume of 1,085,548. The company has a market capitalization of $6.34 billion, a PE ratio of -47.04 and a beta of -0.37. Oruka Therapeutics has a twelve month low of $25.23 and a twelve month high of $115.51. The stock has a 50 day simple moving average of $89.99 and a two-hundred day simple moving average of $67.22.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities research analysts anticipate that Oruka Therapeutics will post -2.42 EPS for the current year.

Insider Buying and Selling

In related news, SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the transaction, the senior vice president owned 15,312 shares of the company’s stock, valued at $1,633,177.92. This trade represents a 39.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the transaction, the insider directly owned 31,771 shares of the company’s stock, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 154,950 shares of company stock valued at $14,102,680 over the last 90 days. Insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Nykredit A S purchased a new position in shares of Oruka Therapeutics during the second quarter worth $29,000. GAMMA Investing LLC raised its holdings in shares of Oruka Therapeutics by 201.6% during the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after purchasing an additional 250 shares during the last quarter. Orion Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the second quarter worth $91,000. Sterling Capital Management LLC raised its holdings in shares of Oruka Therapeutics by 839.0% during the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock worth $138,000 after purchasing an additional 1,485 shares during the last quarter. Finally, Natural Investments LLC purchased a new position in shares of Oruka Therapeutics during the second quarter worth $202,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Key Headlines Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Strong psoriasis efficacy: In the ongoing Phase 2b EVERLAST-B trial, 61% of patients receiving the 600 mg dose achieved complete skin clearance (PASI 100) at Week 16, while 86% achieved PASI 90. The results were broadly consistent with the earlier EVERLAST-A study. Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001
• Positive Sentiment: Potentially meaningful commercial opportunity: Guggenheim reportedly estimates ORKA-001 could generate as much as $7 billion in peak sales if successfully developed and commercialized, supporting the bullish reaction to the trial data. Oruka psoriasis treatment could generate $7B in peak sales
• Positive Sentiment: Development milestones remain on track: Management said ORKA-001 could enter Phase 3 testing in the first half of 2027, with 52-week EVERLAST-A data expected in December 2026 and ORKA-002 Phase 2 psoriasis results anticipated in the first quarter of 2027. The reported safety and tolerability profile remained favorable and consistent with the IL-23p19 drug class.
• Positive Sentiment: Analyst support: Wedbush reaffirmed its “outperform” rating and set a $165 price target, implying substantial upside from the roughly $95 share-price reference in the report. Wedbush stock recommendations
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day days-to-cover ratio. This suggests limited evidence that short covering is driving the move, although the figure may reflect a reporting or data issue.
• Negative Sentiment: Oruka remains a clinical-stage biotechnology company, so ORKA-001 still faces Phase 3, regulatory and commercialization risks. The company is also loss-making, and the positive results are interim rather than approval or revenue data.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.